MediWound’s (MDWD) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MediWound (NASDAQ:MDWD) in a research report report published on Friday morning,Benzinga reports. They currently have a $25.00 target price on the biopharmaceutical company’s stock.

MediWound Stock Up 4.4 %

MDWD stock opened at $16.72 on Friday. MediWound has a twelve month low of $11.04 and a twelve month high of $24.00. The business’s fifty day moving average is $17.24 and its 200-day moving average is $17.62. The company has a market cap of $180.34 million, a P/E ratio of -5.77 and a beta of 0.80.

MediWound (NASDAQ:MDWD) last posted its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period last year, the business earned ($0.24) EPS. Research analysts anticipate that MediWound will post -2.6 earnings per share for the current fiscal year.

Institutional Trading of MediWound

Large investors have recently made changes to their positions in the company. ARK Investment Management LLC acquired a new position in MediWound in the third quarter valued at about $1,806,000. State Street Corp grew its position in shares of MediWound by 219.6% in the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after purchasing an additional 45,529 shares during the period. Barclays PLC increased its stake in MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock worth $202,000 after purchasing an additional 8,449 shares in the last quarter. Rosalind Advisors Inc. raised its holdings in MediWound by 22.3% during the 3rd quarter. Rosalind Advisors Inc. now owns 628,050 shares of the biopharmaceutical company’s stock worth $11,343,000 after buying an additional 114,560 shares during the period. Finally, Rhumbline Advisers bought a new position in MediWound in the second quarter valued at approximately $131,000. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.